$CNTA
Centessa Pharmaceuticals plc Stock $cnta

$cnta Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000184790324000167 Filed on November 12, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development		$33.90M
YoY Change		20.27%
% of Gross Profit
Depreciation & Amortization		$236.0K
YoY Change		2.61%
% of Gross Profit
Operating Expenses		$33.90M
YoY Change		20.27%
Operating Profit		-$46.41M
YoY Change		15.41%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		$3.664M
YoY Change		-318.49%
Pretax Income		-$41.96M
YoY Change		1.17%
Income Tax		$608.0K
% Of Pretax Income
Net Earnings		-$42.57M
YoY Change		10.14%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.37
Diluted Earnings Per Share		-$0.37
COMMON SHARES
Basic Shares Outstanding	131.8M shares	113.3M shares
Diluted Shares Outstanding		116.3M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$518.4M
YoY Change		84.3%
Cash & Equivalents		$395.0M
Short-Term Investments		$123.4M
Other Short-Term Assets		$2.674M
YoY Change		-6.47%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets		$568.4M
YoY Change		70.96%
LONG-TERM ASSETS
Property, Plant & Equipment		$821.0K
YoY Change		-25.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$2.231M
YoY Change		6.14%
Total Long-Term Assets		$41.35M
YoY Change		-7.93%
TOTAL ASSETS
Total Short-Term Assets		$568.4M
Total Long-Term Assets		$41.35M
Total Assets		$609.7M
YoY Change		61.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$7.443M
YoY Change		-31.39%
Accrued Expenses		$18.96M
YoY Change		-21.33%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$26.41M
YoY Change		-24.45%
LONG-TERM LIABILITIES
Long-Term Debt		$75.70M
YoY Change		2.3%
Other Long-Term Liabilities		$29.00K
YoY Change		-99.68%
Total Long-Term Liabilities		$75.73M
YoY Change		2.34%
TOTAL LIABILITIES
Total Short-Term Liabilities		$26.41M
Total Long-Term Liabilities		$75.73M
Total Liabilities		$110.6M
YoY Change		-6.27%
SHAREHOLDERS EQUITY
Retained Earnings		-$877.4M
YoY Change		22.52%
Common Stock		$357.0K
YoY Change		31.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$499.1M
YoY Change
Total Liabilities & Shareholders Equity		$609.7M
YoY Change		61.57%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$42.57M
YoY Change		10.14%
Depreciation, Depletion And Amortization		$236.0K
YoY Change		2.61%
Cash From Operating Activities		-$21.39M
YoY Change		-42.79%
INVESTING ACTIVITIES
Capital Expenditures		$34.00K
YoY Change		-15.0%
Acquisitions
YoY Change
Other Investing Activities		$45.00M
YoY Change		-7.7%
Cash From Investing Activities		$44.96M
YoY Change		-7.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		246.0M
YoY Change		1567.68%
NET CHANGE
Cash From Operating Activities		-21.39M
Cash From Investing Activities		44.96M
Cash From Financing Activities		246.0M
Net Change In Cash		269.6M
YoY Change		933.98%
FREE CASH FLOW
Cash From Operating Activities		-$21.39M
Capital Expenditures		$34.00K
Free Cash Flow		-$21.42M
YoY Change		-42.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2231000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	29000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	110578000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.002
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	184469623	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	131659103	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	131659103	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	98774827	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	357000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1374058000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2095000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-877373000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	499137000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	609715000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4550000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-122634000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2826000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-26200000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-42566000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	177000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7559000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-419000	usd
	dei	Document Type DocumentType	10-Q
	dei	City Area Code CityAreaCode	(617)
	dei	Local Phone Number LocalPhoneNumber	468-5770
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1612294
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3rd Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cheshire
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	WA14 2DT
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	cnta	Tax Incentive Receivable Current TaxIncentiveReceivableCurrent	37818000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15886000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20725000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	568364000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	315092000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	821000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1039000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11244000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11914000	usd
CY2024Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	27055000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	29647000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2554000	usd
CY2024Q3	us-gaap	Assets Assets	609715000	usd
CY2023Q4	us-gaap	Assets Assets	360246000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11815000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-124428000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-114248000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-498000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1241000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1100000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1035000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	602000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2276000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-123826000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-111972000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.15
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.15
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108571742	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108571742	shares
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	499137000	usd
	dei	Entity File Number EntityFileNumber	001-40445
	dei	Entity Address Address Line2 EntityAddressAddressLine2	1 Ashley Road
	dei	Entity Address Address Line3 EntityAddressAddressLine3	Altrincham
	dei	Entity Address Country EntityAddressCountry	GB
	dei	Country Region CountryRegion	1
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	128519000	usd
CY2024Q3	cnta	Tax Incentive Receivable Current TaxIncentiveReceivableCurrent	34029000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	7443000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18963000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27570000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	26406000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	39385000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	75700000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	75700000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8443000	usd
CY2024Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	33903000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12502000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12019000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-126475000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-136105000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2281000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-140448000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1794000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96648110	shares
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4664000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8453000	usd
CY2024Q3	cnta	Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Aggregate Intrinsic Value Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsAggregateIntrinsicValueVested	0	usd
CY2024Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1587000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-412000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	300000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	912000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-42566000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	29000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.002
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	152500000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	98774827	shares
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	286965000	usd
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	CENTESSA PHARMACEUTICALS PLC
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	131845476	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	395026000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	128030000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	123423000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8888000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	124002000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	987423000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1493000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-752945000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	236244000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	360246000	usd
CY2023Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	28190000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	89370000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	94689000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37105000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41416000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-46405000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-40209000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3340000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2953000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	9171000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7543000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	2557000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	2541000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	7611000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	7336000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1677000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-41958000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-41474000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	608000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-38648000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-412000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-419000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	912000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	500000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-167000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42066000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38815000	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116253902	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116253902	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95589181	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95589181	shares
	dei	Entity Central Index Key EntityCentralIndexKey	0001847903
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	273000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3664000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	252000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.20
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.20
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96648110	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	276606000	usd
CY2023Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	701000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	100000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	252000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-38648000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	259390000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	236244000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6311000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25218000	usd
	cnta	Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Aggregate Intrinsic Value Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsAggregateIntrinsicValueVested	0	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4445000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-498000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	300000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1100000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-124428000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	499137000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	336169000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	192000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21962000	usd
	cnta	Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Aggregate Intrinsic Value Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsAggregateIntrinsicValueVested	0	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1525000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1241000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	300000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1035000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-114248000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	259390000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-124428000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-114248000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	25218000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	21962000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	712000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	564000	usd
	cnta	Financial Instruments Gain Loss From Change In Fair Value FinancialInstrumentsGainLossFromChangeInFairValue	0	usd
	cnta	Financial Instruments Gain Loss From Change In Fair Value FinancialInstrumentsGainLossFromChangeInFairValue	-4200000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2255000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-26380000	usd
	cnta	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	-5494000	usd
	cnta	Increase Decrease In Tax Incentive Receivables IncreaseDecreaseInTaxIncentiveReceivables	4157000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5730000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3211000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	225000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1968000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4728000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3308000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-9963000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2841000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	230000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	95000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-99255000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-129292000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	140533000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	194836000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	146834000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	86248000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	141000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6267000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-108729000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5885000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	192000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-3731000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	361789000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14756000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1805000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1119000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	266996000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-222146000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	128030000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	393644000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	395026000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171498000	usd
	us-gaap	Interest Paid Net InterestPaidNet	7611000	usd
	us-gaap	Interest Paid Net InterestPaidNet	7336000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	11000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	2947000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1201000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	785000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9711000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-877400000	usd
CY2024Q3	cnta	Cash And Cash Equivalents And Short Term Investments CashAndCashEquivalentsAndShortTermInvestments	518400000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company’s cash, cash equivalents and short-term investments are held by financial institutions primarily in the United States and the United Kingdom. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institutions are financially sound, and accordingly, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on previously reported net loss or comprehensive loss.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited interim consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, an evaluation of estimates and judgments are required, including those related to accrued research and development expenses, the Note Purchase </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement, share-based compensation and tax related matters. Estimates are based on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div>
	us-gaap	Depreciation Depreciation	252000	usd
	us-gaap	Depreciation Depreciation	208000	usd
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	460000	usd
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	356000	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20499338	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18595661	shares
CY2024Q3	cnta	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	5832000	usd
CY2023Q4	cnta	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	16123000	usd
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	1366000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1651000	usd
CY2024Q3	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	6014000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	1330000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2674000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1621000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15886000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20725000	usd
CY2024Q3	cnta	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	10800000	usd
CY2023Q4	cnta	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	18814000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6158000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6733000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1015000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1072000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	577000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	505000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	413000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	446000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18963000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27570000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1535000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1501000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	714000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	462000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	821000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1039000	usd
CY2024Q3	us-gaap	Purchase Obligation PurchaseObligation	59500000	usd
CY2024Q3	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	50600000	usd
CY2024Q3	cnta	Purchase Obligation To Be Paid Year One Through Five PurchaseObligationToBePaidYearOneThroughFive	8800000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2023Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	18922	sqft
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1600000	usd
CY2023Q1	cnta	Operating Lease Expense Year10 OperatingLeaseExpenseYear10	1900000	usd
CY2023Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	700000	usd
CY2023Q1	cnta	Lessee Operating Lease Number Of Options To Extend LesseeOperatingLeaseNumberOfOptionsToExtend	1	extensionterm
CY2023Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11200000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	9000000.0	usd
CY2023Q4	cnta	Sublease Agreement Term SubleaseAgreementTerm	P5Y
CY2023Q4	cnta	Number Of Square Feet To Sublease NumberOfSquareFeetToSublease	4242	sqft
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11244000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	577000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8443000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	9020000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y3M18D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1197
	us-gaap	Operating Lease Cost OperatingLeaseCost	1498000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	999000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	11000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	43000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	20000	usd
	us-gaap	Sublease Income SubleaseIncome	263000	usd
	us-gaap	Sublease Income SubleaseIncome	0	usd
	us-gaap	Lease Cost LeaseCost	1250000	usd
	us-gaap	Lease Cost LeaseCost	1062000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	400000	usd
CY2024Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	88000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1634000	usd
CY2024Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	355000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1667000	usd
CY2024Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	362000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1700000	usd
CY2024Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	370000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1734000	usd
CY2024Q3	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	345000	usd
CY2024Q3	cnta	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	7290000	usd
CY2024Q3	cnta	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	0	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14425000	usd
CY2024Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	1520000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5405000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	9020000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	577000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8443000	usd
CY2024Q3	cnta	Loss Contingency Claims Dismissed Plaintiff Statement Amendment Period LossContingencyClaimsDismissedPlaintiffStatementAmendmentPeriod	P21D
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8453000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7559000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25218000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21962000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16069015	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.09
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4130400	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.49
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1054246	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	620269	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.56
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18524900	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.45
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10728788	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.41
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y10M24D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	18524900	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.45
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.84
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	34600000	usd
CY2024Q3	us-gaap	Share Price SharePrice	15.99
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	160300000	usd
CY2021Q1	srt	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	860000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.01
	cnta	Share Based Compensation Arrangement By Share Based Payment Award Multiplier For Initial Number Of Shares Reserved ShareBasedCompensationArrangementByShareBasedPaymentAwardMultiplierForInitialNumberOfSharesReserved	2
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2024Q3	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	2708415	shares
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001847903-24-000167-index-headers.html	Edgar Link	pending
0001847903-24-000167-index.html	Edgar Link	pending
0001847903-24-000167.txt	Edgar Link	pending
0001847903-24-000167-xbrl.zip	Edgar Link	pending
a20240930exhibit311.htm	Edgar Link	pending
a20240930exhibit312.htm	Edgar Link	pending
a20240930exhibit321.htm	Edgar Link	pending
a20240930exhibit322.htm	Edgar Link	pending
cnta-20240930.htm	Edgar Link	pending
cnta-20240930.xsd	Edgar Link	pending
cnta-20240930_g1.jpg	Edgar Link	pending
cnta-20240930_g2.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
cnta-20240930_cal.xml	Edgar Link	unprocessable
cnta-20240930_def.xml	Edgar Link	unprocessable
cnta-20240930_lab.xml	Edgar Link	unprocessable
cnta-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cnta-20240930_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNTA
Centessa Pharmaceuticals plc Stock $cnta

2024 Q4 Form 10-Q Financial Statement

#000184790324000167 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNTA Centessa Pharmaceuticals plc Stock $cnta

2024 Q4 Form 10-Q Financial Statement

#000184790324000167 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNTA
Centessa Pharmaceuticals plc Stock $cnta